BioToxTech Co

BioToxTech Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is 13.63. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -7.04 — a change of -293.57% (higher).

EV/FCF

13.63

YoY

-293.57%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of BioToxTech Co is 2025 13.63 . EV/FCF (Enterprise Value to Free Cash Flow) of BioToxTech Co was 2024 -7.04 . It decreases by -293.57% higher compared to the previous year.

The BioToxTech Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
74.35 KRW
Jan 1, 2019
56.31 KRW
Jan 1, 2020
12.66 KRW
Jan 1, 2021
-11.16 KRW
Jan 1, 2022
-1.71 KRW
Jan 1, 2023
-2.90 KRW
Jan 1, 2024
-7.04 KRW
Jan 1, 2025
13.63 KRW
The BioToxTech Co EV/FCF history
YEAREV/FCFYoY
13.63-293.57%
-7.04+142.52%
-2.90+69.27%
-1.71-84.63%
-11.16-188.14%
12.66-77.51%
56.31-24.26%
74.35+241.90%
21.74+106.77%
10.52-121.65%
-48.56+122.68%
-21.81—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of BioToxTech Co is 13.63 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of BioToxTech Co changed from -7.04 to 13.63, representing a -293.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s BioToxTech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BioToxTech Co

All Key Metrics — BioToxTech Co